HSG Blog

HD Insights Volume 17 (PDF)

For a non-PDF version of HD Insights Vol. 17, click here.

FDA approves deutetrabenazine (AUSTEDO™) to treat chorea

On April 3, 2017, the FDA approved a new drug, deutetrabenazine, to treat HD-associated chorea. By: Sara LaJeunesse, MSc Deutetrabenazine...

Meet the Scientist : Beverly Davidson

VITAL SIGNS NAME: Beverly Davidson, PhD TITLE: Chief Scientific Strategy Officer at the Children’s Hospital of Philadelphia (CHOP); Director of...

Game-changing gene-silencing therapies for HD

VITAL SIGNS NAME: Amber Southwell, PhD TITLE: Assistant Professor of Neuroscience, Burnett School of Biomedical Sciences, University of Central Florida...

Research Round-Up

By: Lise Munsie, PhD In neurons… The HD Induced Pluripotent Stem Cell (iPSC) consortium differentiated HD patient iPSCs into neuronal...

Highlights of CHDI

The 12th Annual CHDI HD Therapeutics Conference was held in St. Julian’s, Malta, April 24–27, 2017. By: Nicholas Caron, PhD...

HD Research Around the World: Brazil

By: Irina Kerkis, PhD Little is known formally about the exact number of HD patients and individuals at risk in...

Highlights from the Journal of HD

By: Jennifer A. Simpson, LMSW and George J. Yohrling, PhD Original Article: Simpson JA, Lovecky D, Kogan J, et al....

Editor’s Letter

Welcome to the 17th edition of HD Insights, timed for release at the 21st International Congress of Parkinson Disease and...

We need you!

HSG currently has two surveys in which your input is invaluable. We know there are a lot of surveys going...

1 2 3 21